Why you need to know the difference
Candida species are the fourth most common cause of hospital-acquired infections and are associated with the highest mortality rates.1 Conventional laboratory methods can take days, forcing physicians to treat patients empirically with broad-spectrum antifungal agents.1,2 Resistance to fluconazole in certain species such as Candida glabrata has led to increased use of newer and more expensive echinocandins. These antifungals may be unnecessary and substantially increase drug costs, or in some cases as with Candida parapsilosis, may be less effective than fluconazole.1
QuickFISH Provides 20 Minute Identification and Differentiation of Candida Species
- Results 2-5 days earlier than conventional methods.
- Allows for early, aggressive and appropriate therapy for patients with C. albicans, C. glabrata or C. parapsilosis candidemia.
- Provide clinician with needed information to help guide proper antifungal therapy (e.g. fluconazole for C. albicans, echinocandin for C. glabrata).